





## Introduction

The clinically used theranostic pair: <sup>68</sup>Ga and <sup>177</sup>Lu have shown how effective theranostic pairs are in medicine. Yet, these complexes can exhibit different pharmacokinetics. An elementally matched theranostic pair would allow for identical complexation chemistry, *in vitro* binding, and *in vivo* pharmacokinetics. These chemical characteristics allows scientists and physicians the ability to imaging treatment assessment, and determine the dosimetry of radiopharmaceuticals




Three radioisotopes of scandium that have the decay properties for potential use in medicine as a theranostic pair compared to <sup>68</sup>Ga/<sup>177</sup>Lu:



- Availability for high radionuclide purity scandium isotopes are limited due to lack of robust production techniques.
- Our goal is to develop a technique to produce high purity radioscandium isotopes from proton irradiation of enriched [<sup>46,50</sup>Ti]TiO<sub>2</sub> targets.

## Production

UAB's TR24 cyclotron



### Production of radioscandium from titanium targets




Figure 2: Production routes of radioscandium isotopes of medical interest from <sup>46</sup>Ti

### Cross-sections for <sup>46</sup>Ti(p,α)<sup>43</sup>Sc and <sup>50</sup>Ti(p,α)<sup>47</sup>Sc




Figure 3: Cross sections for <sup>47</sup>Sc and <sup>43</sup>Sc on <sup>46,50</sup>Ti

## Purification





Figure 5: Elution profile for enriched [<sup>50</sup>Ti]TiO<sub>2</sub> productions. FT is the flow through, followed by the elutions discussed in the separations section.




Figure 6: ICPMS elution profile of trace metal contaminants of an enriched [<sup>50</sup>Ti]TiO<sub>2</sub> productions. FT is the flow through, followed by the elutions discussed in the separations section.

	<sup>43</sup> Sc(mCi)		<sup>48</sup> V(μCi)			
Starting	13.5	20.1	14.6	59.9	75.3	77.2
FT	.576	0	.924	27.3	22.7	35.6
E1	.174	0	.037	26.2	57.5	59.1
E2	.807	0	.010	26.2	37.8	35.9
E3	.032	.077	.075	0	0	0
E4	12.6	16.9	12.8	0	0	0
E5	.024	.371	.182	0	0	0
E6	.134	.027	0	0	0	0

	<sup>43</sup> Sc(mCi)		<sup>48</sup> V(μCi)			
Starting	3.03	1.37	2.29	832.2	339.8	414.6
FT	.023	.038	.163	0	249.6	213.4
E1	0	.007	.001	538.6	54.4	1.4
E2	0	.013	.0004	114.1	61.7	93.1
E3	.013	.002	.013	69.6	1.8	0
E4	3.04	1.19	1.75	0.2	0	0
E5	.037	.025	.102	0	0	0
E6	.006	.003	.003	0	0	0




Figure 8: HPGc spectra of the dissolved target and collected <sup>43</sup>Sc from enriched [<sup>46</sup>Ti]TiO<sub>2</sub>




Figure 9: HPGc spectra of the dissolved target and collected <sup>47</sup>Sc from enriched [<sup>50</sup>Ti]TiO<sub>2</sub>

Radionuclide	<sup>43</sup> Sc	<sup>44m</sup> Sc	<sup>44g</sup> Sc	<sup>46</sup> Sc	<sup>47</sup> Sc	<sup>48</sup> Sc	Total radioscandium
Activity (mCi) [ <sup>46</sup> Ti]	12.9	0.031	0.141	0.38	0.11	0.07	13.1
Percentage	98.8	0.02	1.08	0	0.08	0	100
Activity (μCi) [ <sup>50</sup> Ti]	Decayed	65.8	65.8	39	1786.9	8.8	1966.1
Percentage	Decayed	3.3	3.3	1.9	91	0	100

## References

• Kratochwil, C., et al. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with <sup>177</sup>Lu-Labeled PSMA-617. *J Nucl Med* 2016, 57 (8), 1170-6

• Domnanich, K. A.; Eichler, R.; Müller, C.; Jordi, S.; Yakusheva, V.; Braccini, S.; Behe, M.; Schibli, R.; Türker, A.; van der Meulen, N. P., Production and separation of <sup>43</sup>Sc for radiopharmaceutical purposes. *EJNMMI Radiopharmacy and Chemistry* 2017, 2 (1), 14.

• Rotsch, D. A.; Brown, M. A.; Nolen, J. A.; Brossard, T.; Henning, W. F.; Chernerisov, S. D.; Gromov, R. G.; Greene, J., Electron linear accelerator production and purification of scandium-47 from titanium dioxide targets. *Appl Radiat Isot* 2018, 131, 77-82.

• Loveless, C. S., et al. (2020). "Cyclotron Production and Separation of Scandium Radionuclides from Natural Titanium Metal and Titanium Dioxide Targets." *Journal of Nuclear Medicine*

## Recycling




Figure 10: Percent recovery for [<sup>50</sup>Ti]TiO<sub>2</sub> from 3 bombardments





Figure 11: Percent recovery for [<sup>46</sup>Ti]TiO<sub>2</sub> from 2 bombardments



Average recovery: 96.6±4%


Average recovery: 96.5±3.5%

	Cycle: 1 (ppb)	Cycle: 4 (ppb)	Cycle: 6 (ppb)
Zn	430.8	47.6	29.7
Cr	311.3	<15	<15
Mn	340.1	<15	<15
Fe	1,433.1	129.1	<15
Ni	189.5	<15	<15
Cu	263.9	11.6	<15
Pb	2,172.3	<15	<15
W	10,170.7	53.1	32.7

## Radiolabeling and phantom

A serial dilution of DOTA was performed in 0.25M ammonium acetate pH 4. Equal amounts of <sup>43,47</sup>Sc were added and complexed at 95°C at 800 rpm for 30 minutes. SG-iTLC in 1M citrate buffer was used to determine percent complexation.

Derenzo phantoms were prepared with a solution MQ water with 100 μCi of either [<sup>68</sup>Ga] or [<sup>43</sup>Sc]. The phantoms were imaged on a SODIE PET/CT small animal scanner for a 1-hour static scan.



<sup>43</sup>Sc-DOTA ESA: 160.29 mCi/μmol  
<sup>47</sup>Sc-DOTA ESA: 91.73 mCi/μmol

## Conclusions

- Production of high purity <sup>43,47</sup>Sc from proton bombardment of enriched [<sup>46,50</sup>Ti]TiO<sub>2</sub> has been shown to be feasible with high recovery from recycling
- Effective radiolabeling of <sup>43,47</sup>Sc produced from [<sup>46,50</sup>Ti]TiO<sub>2</sub> has shown promising application for high purity <sup>43,47</sup>Sc

## Acknowledgements

This project was supported by the DOE isotope program through grant DESC0020197 (P.I. Lapi). This work was supported in part by Department of Energy Isotope Program's DE-SC0022550 and the Horizon-broadening Isotope Production Pipeline Opportunities (HIPPO) program. The authors acknowledge the support of all team members of Dr. Lapi's group, UAB cyclotron Facility and the UAB machine shop.